18.06 12:33 | dpa-AFX: ANALYSE-FLASH: Goldman belässt Astrazeneca auf 'Buy' - Ziel 15200 Pence |
18.06 12:33 | dpa-AFX: Goldman belässt Astrazeneca auf 'Buy' - Ziel 15200 Pence |
18.06 08:31 | dpa-AFX: AstraZeneca: Phase III Truqap Trial Plus Chemotherapy Fails To Meet Primary Goals In Breast Cancer |
18.06 08:06 | dpa-AFX: *ASTRAZENECA : PHASE III TRIAL OF TRUQAP PLUS CHEMOTHERAPY IN ADVANCED BREAST CANCER FAILS TO MEET MAIN GOAL |
18.06 08:06 | dpa-AFX: *ASTRAZENECA SAYS CAPITELLO-290 PHASE III TRIAL FOR TRUQAP + CHEMOTHERAPY FAILS TO MEET DUAL PRIMARY ENDPOINTS OF IMPROVEMENT IN OVERALL SURVIVAL |
17.06 08:25 | dpa-AFX: AstraZeneca's Imfinzi Plus Chemotherapy Approved In The US For Endometrial Cancer |
17.06 08:02 | dpa-AFX: *ASTRAZENECA : FDA OKS IMFINZI PLUS CHEMOTHERAPY FOR MISMATCH REPAIR DEFICIENT ADVANCED OR RECURRENT ENDOMETRIAL CANCER |
17.06 08:02 | dpa-AFX: *ASTRAZENECA SAYS IMFINZI PLUS CHEMOTHERAPY APPROVED IN THE US FOR ENDOMETRIAL CANCER |
16.06 18:04 | dpa-AFX: AstraZeneca's Calquence Combo Cuts Progression Risk By 27% In Mantle Cell Lymphoma Trial |
13.06 03:13 | dpa-AFX: FDA Approves AstraZeneca's Farxiga For Pediatric Use In Type-2 Diabetes |
10.06 13:30 | dpa-AFX: AstraZeneca's Tagrisso Gets Priority Review In US In Stage III EGFR-mutated Lung Cancer |
10.06 13:05 | dpa-AFX: *ASTRAZENECA SAYS TAGRISSO GRANTED PRIORITY REVIEW IN US FOR PATIENTS WITH STAGE III EGFR-MUTATED LUNG CANCER |
10.06 07:34 | dpa-AFX: ANALYSE-FLASH: Berenberg hebt Ziel für Astrazeneca auf 15000 Pence - 'Buy' |
10.06 07:34 | dpa-AFX: Berenberg hebt Ziel für Astrazeneca auf 15000 Pence - 'Buy' |
10.06 07:00 | dpa-AFX: *BERENBERG RAISES ASTRAZENECA PRICE TARGET TO 15000 (13000) PENCE - 'BUY' |
10.06 07:00 | dpa-AFX: *BERENBERG HEBT ZIEL FÜR ASTRAZENECA AUF 15000 (13000) PENCE - 'BUY' |
07.06 09:29 | dpa-AFX: ANALYSE-FLASH: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 13000 Pence |
07.06 09:29 | dpa-AFX: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 13000 Pence |
06.06 13:02 | dpa-AFX: *I-MAB APPOINTS PHILLIP DENNIS AS CHIEF MEDICAL OFFICER, EFFECTIVE JUNE 17 |
05.06 13:44 | dpa-AFX: ANALYSE-FLASH: Deutsche Bank belässt Astrazeneca auf 'Hold' - Ziel 11000 Pence |
|